Press release
Rising Tobacco Consumption Fuels Growth In The Non-Small Cell Lung Cancer (NSCLC) Market: The Driving Engine Behind Non-Small Cell Lung Cancer (NSCLC) Market Evolution in 2025
Non Small Cell Lung Cancer NSCLC Market Size
Non-Small Cell Lung Cancer (NSCLC) Market Size Growth Forecast: What to Expect by 2025?
The market size for non-small cell lung cancer (NSCLC) has seen substantial growth in the past few years. It is projected to expand from $20.1 billion in 2024 to $22.35 billion in 2025, with a compound annual growth rate (CAGR) of 11.1%. The acceleration in growth during the past period is credited to advancements in immunotherapy, genomic profiling, precision medicine, the broadening of clinical trials, and initiatives promoting smoking cessation.
How Will the Non-Small Cell Lung Cancer (NSCLC) Market Size Evolve and Grow by 2029?
Anticipated to witness swift expansion in the coming years, the market size for non-small cell lung cancer (NSCLC) is predicted to reach $33.29 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 10.5%. The progressive surge during the forecast period can be credited to the development of combination therapies, the incorporation of artificial intelligence (AI), the broadening of personalized vaccines, global research collaborations, and a focus on patient-centric care. The forecast period is also set to observe significant trends such as the inclusion of telemedicine in oncology, the progression of liquid biopsy technologies, advancements in diagnostic technologies, the uptake of minimally invasive surgical methods, and immune checkpoint inhibitors.
View the full report here:
https://www.thebusinessresearchcompany.com/report/non-small-cell-lung-cancer-nsclc-global-market-report
What Drivers Are Propelling the Growth of Non-Small Cell Lung Cancer (NSCLC) Market Forward?
The escalation in tobacco use is anticipated to spur the expansion of the non-small cell lung cancer (NSCLC) market. This refers to the utilization of tobacco products which includes smoking, chewing, and ing, thus delivering nicotine and other chemicals into the human system. Tobacco smoke which contains various carcinogens is known to harm the DNA in lung cells, promoting mutations and the unruly enlargement of cancerous cells such as non-small-cell lung cancer (NSCLC). As an illustration, findings from the 2024 National Youth Tobacco Survey by the US Food and Drug Administration (USFDA) in October 2024, showed that 1.1% of all students (roughly 2.25 million) admitted to using tobacco products, 10.1% of high school students (approximately 1.58 million) and 5.4% of middle school students (around 640,000) used tobacco. Additionally, 2.8% of students (about 760,000) reported using any flammable tobacco product, while 3.0% (approximately 840,000) reported using multiple tobacco products. Hence, the upswing in tobacco use acts as a driving factor for the enlargement of the non-small cell lung cancer (NSCLC) market. Non-Small Cell Lung Cancer (NSCLC) Market Driver: Augmenting Air Pollution Levels Tied To Increased Non-Small Cell Lung Cancer (NSCLC) Cases
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13232&type=smp
Which Emerging Trends Are Transforming the Non-Small Cell Lung Cancer (NSCLC) Market in 2025?
Prominent businesses in the non-small cell lung cancer (NSCLC) market are concentrating on the development of a range of treatment alternatives, such as monotherapy treatments, to establish a competitive advantage. Monotherapy treatment refers to the use of a single drug or therapy for a specific illness or ailment, employing a single technique or treatment method rather than a combination of interventions. As an example, in June 2022, the European Commission (EC), a governing authority based in Belgium, granted approval to Novartis AG, a pharmaceutical firm from Switzerland, for Tabrecta (capmatinib), a medication designed to treat adult patients with advanced non-small cell lung cancer with METex14 skipping. This provides a new targeted treatment option for patients in Europe who have received prior treatment and have advanced non-small cell lung cancer (NSCLC) that has mutations leading to MET exon 14 (METex14) skipping. It is currently the most widely used targeted treatment for advanced NSCLC, characterized by changes that cause METex14 skipping.
What Are the Key Segments in the Non-Small Cell Lung Cancer (NSCLC) Market?
The non-small cell lung cancer (NSCLC) market covered in this report is segmented -
1) By Type: Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, Other Types
2) By Therapy: Radiotherapy, Laserthearpy, Photodynamic Therapy (PDT), Other Therapies
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Other Distribution Channels
Subsegments:
1) By Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma
2) By Large Cell Carcinoma: Undifferentiated Large Cell Carcinoma, Large Cell Neuroendocrine Carcinoma
3) By Adenocarcinoma: Invasive Adenocarcinoma, Bronchioloalveolar Carcinoma
4) By Other Types: Mixed Cell Type Carcinoma, Sarcomatoid Carcinoma
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13232&type=smp
Who Are the Key Players Shaping the Non-Small Cell Lung Cancer (NSCLC) Market's Competitive Landscape?
Major companies operating in the non-small cell lung cancer (NSCLC) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines
What Geographic Markets Are Powering Growth in the Non-Small Cell Lung Cancer (NSCLC) Market?
North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (NSCLC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13232
"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rising Tobacco Consumption Fuels Growth In The Non-Small Cell Lung Cancer (NSCLC) Market: The Driving Engine Behind Non-Small Cell Lung Cancer (NSCLC) Market Evolution in 2025 here
News-ID: 4125761 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for NSCLC
NSCLC Treatment Market to Reach USD 55.30B by 2035
Non-Small Cell Lung Cancer Treatment Market: Growth Drivers, Innovation, and the Future of Lung Cancer Care
The Non-Small Cell Lung Cancer (NSCLC) Treatment Market is undergoing a profound transformation as advances in diagnostics, targeted therapies, and immuno-oncology redefine how lung cancer is managed globally. NSCLC accounts for nearly 85% of all lung cancer cases, making it the most prevalent and commercially significant segment of the lung cancer therapeutics market.
Historically, NSCLC was…
NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - H …
DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets.
With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a…
Huateng Pharma Supplies Intermeidates of Pemetrexed Against NSCLC
Pemetrexed disodium is a drug successfully developed by Eli Lilly in the United States for the treatment of tumors, patent protection to January 2017. Pemetrexed disodium is a multi-targeted anti-folate agent with a core pyrrolopyrimidine moiety in its structure. It is a dual inhibitor of nucleotide synthase/dihydrofolate reductase, which inhibits cell replication by disrupting the normal process of folate-dependent metabolism in cells and simultaneously blocking three different enzyme targets critical…
NSCLC Market Global Industry Analysis and Forecast Till 2027
Any type of epithelial lung cancer that isn't small cell lung cancer is referred to as NSCLC (SCLC). Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common kinds of NSCLC, although there are several more types that are less common, and all types can occur in atypical histologic variants.
Request Sample Copy of this Report: https://www.infinitybusinessinsights.com/request_sample.php?id=562904
Top Key Players Included in This Report: Merck KGa, Roche, Nlyte, Taxotere,…
Targeted Drugs for NSCLC Market Size by 2025: QY Research
Global Targeted Drugs for NSCLC market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail…
"NSCLC - Market Outlook and Competitive Landscape Report 2015 – 2030 "
Report Snapshot:
NSCLC is the most common form of lung cancer, accounting for approximately 85% of all types and subtypes of lung cancer. It grows and spreads more slowly than small cell lung cancer. Early stage disease is associated with uncommon specific symptoms; hence roughly ~50% to 73% of cases are not being diagnosed until the disease is at an advanced stage when the chances for cure or significant patient benefit…
